证券代码：688273 证券简称：麦澜德 公告编号：2025-004 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 | | --- | --- | | 回购方案实施期限 | 待第二届董事会第八次会议审议通过后 12 个月 | | 预计回购金额 | 2,000 万元~4,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 103.00 | | 累计已回购股数占总股本比例 | 1.03% | | 累计已回购金额 | 2,002.1020 万元 | | 实际回购价格区间 | 18.57 元/股~19.99 元/股 | 一、 回购股份的基本情况 2024 年 6 月 24 日，南京麦澜德医疗科技股份有限公司（以下简称"公 ...

Financial Performance - Total operating revenue for 2024 reached 422.68 million yuan, a year-on-year increase of 24.02%[4] - Operating profit was 112.79 million yuan, reflecting a growth of 10.06% compared to the previous year[4] - Net profit attributable to shareholders of the parent company was 102.17 million yuan, up 13.75% year-on-year[4] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was 90.44 million yuan, an increase of 26.42%[4] - Basic earnings per share were 1.0369 yuan, representing a 15.44% increase from the previous year[4] - The weighted average return on net assets increased by 1.01 percentage points to 7.64%[4] Assets and Equity - Total assets at the end of the reporting period amounted to 1,547.64 million yuan, a growth of 0.89% from the beginning of the period[4] - Equity attributable to shareholders of the parent company decreased by 2.45% to 1,312.79 million yuan[4] Business Strategy - The company strengthened brand building and optimized sales channels, leading to rapid growth in sales of reproductive rehabilitation products and consumables[6] Cautionary Note - The company warns that the financial data presented are preliminary and subject to final audit, urging investors to be aware of investment risks[7]

证券代码：688273 证券简称：麦澜德 公告编号：2025-002 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 案之日起 12 个月内。具体内容详见公司于 2024 年 7 月 2 日在上海证券交易所网 站（www.sse.com.cm）披露的《关于以集中竞价交易方式回购股份的回购报告书》 （公告编号：2024-041）。 公司 2024 年半年度权益分派实施后，公司以集中竞价交易方式回购股份价格 上限由不超过人民币 32.00 元/股（含）调整为不超过人民币 31.61 元/股（含）。具 体内容详见公司于 2024 年 10 月 12 日在上海证券交易所网站（www.sse.com.cm） 披露的《关于 2024 年半年度权益分派实施后调整回购价格上限的公告》（公告编 号：2024-061）。 二、 回购股份的进展情况 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 | | -- ...

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 2024年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规 则》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》等有关法 律、法规的规定，南京证券股份有限公司（以下简称"保荐机构"或"南京证券"）作 为正在履行南京麦澜德医疗科技股份有限公司（以下简称"麦澜德"或"公司"）持续 督导工作的保荐机构，对公司2024年1月1日至本次现场检查期间（以下简称"本持续 督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 2024年12月25日至2024年12月30日 （四）现场检查人员 张红、刘姝含、操函希 （五）现场检查内容 公司治理和内部控制情况、信息披露情况、公司的独立性以及与控股股东、实 际控制人及其他关联方资金往来情况、募集资金使用情况、关联交易、对外担保、 重大对外投资情况、公司经营状况等。 （六）现场检查手段 （一）保荐机构 南京证券股份有限公司 （二）保荐代表人 李建勤、张红 （三）现场检查时间 1、与公司部分董事、高级管理人员进行访谈 ...

Group 1: Company Overview and Strategy - Nanjing Maillande Medical Technology Co., Ltd. focuses on the promotion of the "Magnetic Electric Thermal Imaging · Smart Integration PI-ONE" pelvic floor intelligent diagnosis and treatment system, enhancing market competitiveness and establishing a solid industry moat [2][3] - The company collaborates with the National Health Commission's research institute to promote national projects, leveraging academic channels for expansion [3] - The new product rollout is planned and executed in phases, aligning with market feedback and company expectations [3] Group 2: Product Applications and Market Insights - The reproductive anti-aging products are widely used in medical beauty institutions and reproductive centers, with a direct sales model supplemented by distribution [4] - The market for reproductive health is in the introduction and growth stages, driven by increasing awareness and demand among women for reproductive health services [4][5] - The electric ultrasound therapy device targets populations with reproductive function decline, while the uterine recovery device is aimed at postpartum and post-abortion fertility preservation [4] Group 3: Financial Performance and Market Challenges - Approximately 85% of the company's business comes from the hospital sector, with external market performance affected by declining birth rates, although business volume has stabilized in recent years [5] - The aging population and rising health awareness are contributing to an increasing number of women seeking screening and treatment for pelvic floor dysfunction (PFD) [5] Group 4: Future Directions and Risk Management - The company maintains a strategy of "internal growth and external mergers," actively seeking new project opportunities that align with its strategic direction [4] - Caution is exercised in evaluating market conditions, project risks, and potential returns before pursuing investments and acquisitions [4][6] - Investors are advised to be aware of the risks associated with industry forecasts and company development strategies, as these do not constitute commitments from the company [6]

Group 1: Financial Performance - In the first three quarters of 2024, the company achieved a revenue of approximately 330 million CNY, representing a year-on-year growth of 13.81% [2] - The net profit attributable to the parent company was approximately 96.07 million CNY, with a year-on-year increase of 13.37% [3] Group 2: Business Development Directions - The future business development and growth logic are primarily driven by three segments: pelvic floor rehabilitation, reproductive anti-aging, and rehabilitation [3] - The pelvic floor segment is experiencing increasing demand due to the aging population and rising health awareness, with a growing number of women actively screening and treating pelvic floor dysfunction [3] - The reproductive anti-aging segment has formed an integrated ecosystem since the launch of its first product in 2022, generating over 50 million CNY in revenue in the first half of 2024 [4] Group 3: Product Innovations - The company launched the "Magnetic-Electric Thermal Imaging · Smart Integration PI-ONE" system in the first quarter, which includes three new products for pelvic floor rehabilitation [6] - The new pelvic floor rehabilitation products aim to provide a comprehensive solution, integrating various technologies for personalized treatment plans [7] Group 4: Market Strategy - The company plans to continue focusing on women's health and beauty, actively expanding into new technologies, products, markets, and business areas [5] - Despite a slowdown in the overall growth of the pelvic floor rehabilitation industry, the company has maintained a relatively stable growth rate compared to peers, indicating a strong market position [5] Group 5: Revenue Composition - Revenue from consumables accounts for approximately 25% of total revenue, with a stable gross margin [7]

进展公告 证券代码：688273 证券简称：麦澜德 公告编号：2024-068 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应在每个月的前 3 个交易日内公告截至上月 末的回购进展情况。现将公司回购股份进展的具体情况公告如下： 2024 年 11 月，公司未通过集中竞价交易方式回购股份。 截至 2024 年 11 月 30 日，公司通过上海证券交易所系统以集中竞价交易方式 累计回购公司股份 1,030,000 股，占公司总股本 100,000,000 股的比例为 1.03%，回 购成交的最高价为 19.99 元/股，最低价为 18.57 元/股，支付的资金总额为人民币 20,021,020.17 元（不含印花税、交易佣金等交易费用）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 | | ...

Group 1: Business Overview - The company focuses on reproductive anti-aging as its second strategic product line after pelvic floor rehabilitation, with significant clinical efficacy and promotion methods [1] - The reproductive anti-aging segment has gained widespread market recognition, forming an integrated ecological chain for women's reproductive health [2] - The company provides comprehensive solutions for reproductive anti-aging needs, utilizing key technologies such as electricity, magnetism, high frequency, and focused ultrasound [2] Group 2: Target Demographics and Market Potential - The products are suitable for women in various stages post-puberty, especially those in perimenopause experiencing reproductive system decline [2] - The market for reproductive health solutions is growing annually, driven by increasing awareness and demand for improving reproductive health and alleviating menopausal symptoms [3] Group 3: Financial Performance and Challenges - The company's revenue saw a slight decline due to changes in the internal and external business environment, alongside a significant increase in R&D expenses, which accounted for approximately 17% of total revenue [4] - The decision to terminate the 2023 equity incentive plan was influenced by the company's inability to meet performance targets and significant fluctuations in stock price [4] Group 4: Sales Strategy and Market Approach - The company employs a market penetration strategy, starting with tertiary hospitals to establish regional model clients before expanding to secondary and primary hospitals, community health institutions, and clinics [5] - The sales model is primarily direct sales, supplemented by distribution for hospital markets, with a focus on building brand influence [5] Group 5: Future Developments and Risk Management - The company is committed to developing new products for women's health throughout their life cycle, with details on new products expected in the 2024 annual report [5] - The company maintains a cautious approach to investments and acquisitions, evaluating market conditions, project risks, and potential returns to mitigate investment risks [5]

Group 1: Industry Overview - The medical device industry is relatively stable, with long-term growth expected despite short-term challenges due to economic cycles and industry changes [2] - The company aims to reshape growth, focusing on four main areas for future development [2] Group 2: Key Business Segments - **Pelvic Floor Segment**: The demand for pelvic floor dysfunction (PFD) treatment is increasing due to aging populations and rising health awareness, with a growing number of women actively seeking screening and treatment [2][5] - **Reproductive Anti-Aging Segment**: Revenue from reproductive recovery and anti-aging products exceeded 50 million yuan in the first half of 2024, driven by increasing awareness and demand among women [3] - **Rehabilitation Segment**: The company is focusing on a specialized rehabilitation track, integrating various technologies to meet diverse clinical needs [4] Group 3: Market Dynamics - The hospital market accounts for over 85% of the company's pelvic rehabilitation business, with a noticeable decline in performance in the outpatient market due to decreasing birth rates [4] - The company plans to expand into consumer healthcare by integrating various health solutions, addressing women's health and beauty needs [5] Group 4: Competitive Landscape - The company views competition as a necessary driver for industry development and is committed to continuous innovation and building a robust technology platform to enhance its competitive edge [6] - Ongoing technological breakthroughs and product innovations are essential for raising industry standards and ensuring sustainable growth [6] Group 5: Risk Considerations - Any forecasts regarding industry trends or company strategies should not be interpreted as commitments or guarantees regarding future performance [6]

北京市中伦律师事务所 关于南京麦澜德医疗科技股份有限公司 2024 年第四次临时股东大会的 本法律意见书仅就本次股东大会的召集人资格、召集和召开程序、出席本次 股东大会人员的资格、会议表决程序是否符合法律、法规、规范性文件及《公司 章程》的规定以及表决结果是否合法有效发表意见，而不对本次股东大会所审议 的议案内容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发 表意见。 本法律意见书仅供公司本次股东大会之目的使用，未经本所书面同意，不得 用作其他任何目的。 为出具本法律意见书，本所律师列席了本次股东大会，并根据有关法律、法 1 法律意见书 规、规范性文件的规定和要求，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神，对公司提供的与本次股东大会有关的文件和事实进行了核查和验证。 在本所律师对公司提供的有关文件进行核查和验证的过程中，本所假设： 1. 提供给本所的文件中的所有签署、盖章及印章都是真实的，所有作为正 本提供给本所的文件都是真实、准确、完整的； 法律意见书 致：南京麦澜德医疗科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》及中国证券监 ...